Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 2Genitourinary 1

Conditions

Prostatic Neoplasms 1

Interventions

Docetaxel 390pembrolizumab 326Prednisone 285Gemcitabine 273enzalutamide 256Radiotherapy 251Nivolumab 248Magnetic Resonance Spectroscopy 247Cisplatin 209Abiraterone Acetate 198Radiosurgery 184Leuprolide 182Sunitinib 169Carboplatin 161bicalutamide 148Goserelin 145Androgen Antagonists 142Specimen Handling 138Ipilimumab 128Paclitaxel 125Cyclophosphamide 116acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 110Bevacizumab 109Everolimus 107apalutamide 99abiraterone 99cabozantinib 98atezolizumab 97Sorafenib 97Radiation 89

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Cesium-131 × Genitourinary × Clear all
NCT02290366 2022-08-29

Prospective Evaluation of Focal Brachytherapy Using Cesium-131 For Patients With Low Risk Prostate Cancer

University of Pittsburgh

Phase NA Withdrawn
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡